Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Griseofulvin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Griseofulvin Tablets contain griseofulvin which is an antifungal antibiotic. Griseofulvin kills the fungi that cause infections of:
e Griseofulvin Tablets
Do not take Griseofulvin Tablets
82-83/L/x/2
1/4
–
oral contraceptives (the pill). You will need an additional method of contraception, such as condoms while you are taking Griseofulvin Tablets and also during the month after stopping treatment phenylbutazone, a medicine used to treat a type of arthritis phenobarbitone, a medicine used to control epilepsy (fits) ciclosporin, a medicine used to suppress the immune system medicines that thin the blood (e.g.warfarin) any medicines that tend to make you sleepy, such as medication used to help you sleep or calm you down medicines containing alcohol. Griseofulvin Tablets may enhance the effect of alcohol.
Pregnancy and breast-feeding DO NOT take Griseofulvin Tablets if you are pregnant or breast-feeding. Griseofulvin Tablets may cause birth defects and it may affect breast-fed babies. If you become pregnant while taking Griseofulvin Tablets, stop taking them immediately and contact your doctor. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Important information for men and women:
Griseofulvin Tablets
Always take this medicine exactly as your doctor has told you and always read the label. Your doctor will decide on the appropriate dose to suit your condition. Check with your doctor or pharmacist if you are not sure.
2/4
Keep taking the tablets for at least two weeks after all signs of infection have disappeared. You may need to take Griseofulvin every day for many weeks or months while new skin, hair or nails grow. This depends upon the thickness of keratin (hair, nails) at the site of infection.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Do not be alarmed by this list of possible side effects. You may not experience any of them. STOP taking the tablets and seek medical help immediately if you have any of the following allergic reactions:
3/4
–
headache.
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5. 6.
Griseofulvin Tablets Keep out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP. The expiry date refers to the last day of that month. Do not store above 25oC. Store in the original container. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Griseofulvin Tablets contains
82-83/L/x/2
4/4
Griseofulvin 500 mg Tablets comes as tablet containing 500mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Griseofulvin 500 mg Tablets is griseofulvin.
Medicines with the same active substance, strength and form include: Griseofulvin 500mg Tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Griseofulvin 500 mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
The treatment of fungal infections of the skin, scalp, hair or nails where topical therapy is considered inappropriate or has failed.
When griseofulvin is given orally for systemic treatment of fungal infections, it enables newly-formed keratin of the skin, hair and nails to resist attack by the fungi. As the new keratin extends, the old infected keratin is shed. Griseofulvin is effective against the dermatophytes causing ringworm (tinea), including: Microsporum canis and T. Verrucosum.
Griseofulvin is not effective in infections caused by Candida albicans(monilia), Aspergilli, Malassezia furfur (Pityriasis versicolor) and Nocardia species.
Posology
Adults
Normally 500 to 1000 mg daily, but not less than 10 mg/kg bodyweight daily. A single dose daily is often satisfactory, but divided doses may be more effective in patients who respond poorly.
Paediatric population
Usually 10 mg/kg (5 mg/lb) body weight daily in divided doses.
Duration of Treatment
This depends upon the thickness of keratin at the site of infection. For hair or skin at least four weeks treatment is required, whereas toe or fingernails may need six to twelve months treatment. Therapy should be continued for at least two weeks after all signs of infection have disappeared.
Method of administration
For oral administration.
Doses should be taken after meals, otherwise absorption is likely to be inadequate.
Porphyria or severe liver disease. Griseofulvin may cause liver disease to deteriorate, and liver function should be monitored in such conditions.
Systemic Lupus Erythematosus: griseofulvin has been reported to exacerbate the condition.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
There is no evidence of the safety of Griseofulvin in human pregnancy. Griseofulvin is teratogenic in animals and some case reports of human foetal abnormalities have been observed. Therefore, Griseofulvin should not be used in pregnancy, or in women intending to become pregnant within one month following cessation of treatment.
Males should not father children within six months of treatment with Griseofulvin.
Long term administration of high doses of griseofulvin with food has been reported to induce hepatomas in mice and thyroid tumours in rats but not hamsters. The clinical significance of these findings in man is not known. In view of these data, Griseofulvin tablets should not be used prophylactically.
None.
Griseofulvin may decrease the blood level and hence efficacy of certain drugs, which are metabolised by cytochrome P450 3A4. These include oral contraceptives, coumarin anticoagulants and ciclosporin. Appropriate monitoring should be undertaken and dosage should be adjusted as necessary. Additional contraceptive precautions should be taken during griseofulvin treatment and for a month after stopping griseofulvin.
Absorption of griseofulvin is inhibited when phenobarbitone is taken concurrently. The blood level, and hence efficacy, of griseofulvin may also be impaired as the result of concurrent administration of substances such as phenylbutazone and sedative and hypnotic drugs which induce metabolising enzymes.
Patients should be warned that an enhancement of the effects of alcohol by griseofulvin has been reported.
Excipients
This medicine contains 1.55 mg propylene glycol in each tablet.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodiumfree'.
Pregnancy
There is no evidence of its safety in human pregnancy (see contraindications). Griseofulvin has been shown to be teratogenic in mice and rats following administration to pregnant animals. Some casereports suggest that it produces human foetal abnormalities.
As Griseofulvin is capable of inducing aneuploidy (abnormal segregation of chromosomes following cell division) in mammalian cells exposed to the compound in vitro and in vivo, women should be warned that they should not take the drug during pregnancy or become pregnant within one month following cessation of treatment.
Additionally, males should not father children within six months of treatment.
Breast-feeding
It is not known if griseofulvin is excreted in human milk. Safety in children of mothers who are breastfeeding has not been established.
In those rare cases where individuals are affected by drowsiness while taking griseofulvin, they should not drive vehicles or operate machinery.
Diarrhoea, nausea and vomiting are common adverse events.
Headache and gastric discomfort sometimes occur, but usually disappear as treatment continues. On rare occasions urticarial reactions, skin rashes and precipitation of Systemic Lupus Erythematosus have been reported.
Toxic epidermal necrolysis and erythema multiforme have been reported.
Significant elevations in LFTs (greater than three times the upper limit of normal) have been reported very rarely.
There have been reports of central nervous system effects e.g. confusion, dizziness, impaired coordination and peripheral neuropathy.
Leucopenia with neutropenia has been reported.
Photosensitivity reactions can occur on exposure to intense natural or artificial sunlight.
Drowsiness has been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Treatment is unlikely to be required in cases of acute overdosage.
Ask anything about Griseofulvin 500 mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.